Our key finding in breast cancer research—that CIITA expression exhibits a significant association with features of the anti-tumor immune microenvironment and patient prognosis—aligns closely with the broader immunomodulatory role of CIITA observed in recent years across diverse malignancies, including lymphoma, melanoma, and colorectal cancer 27-29. Here, CIITA is linked to melanoma.